Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR Alpha/Beta Depletion PBSC Transplantation for Hematological Malignancies
NCT05735717Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- May 2023
- Primary completion
- Nov 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpha/beta T-cell depleted peripheral blood stem cells in hematological malignancy, acute leukemia, acute myeloid leukemia (AML) and 5 more (8 arms), sponsored by Masonic Cancer Center. Primary endpoint: Rate of Graft-Versus-Host Disease at 100 days. Started May 2023; status: recruiting.
02
Drugs
alpha/beta T-cell depleted peripheral blood stem cells
03
Conditions
hematological malignancyacute leukemiaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT05735717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735717.